A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec

Trial ID or NCT#

NCT04488133

Status

recruiting iconRECRUITING

Purpose

The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received onasemnogene abeparvovec. The secondary objectives of this study are to evaluate the safety and tolerability; clinical outcomes and pharmacodynamics (PD) of nusinersen treatment in participants with SMA who previously received onasemnogene abeparvovec.

Official Title

A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec

Eligibility Criteria

Ages Eligible for Study: 2 Months to 36 Months
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. For all participants: - Genetic documentation of 5q SMA homozygous gene survival motor neuron 1 (SMN1) deletion or mutation, or compound heterozygous mutation - SMN2 copy number of ≥1 - ≤36 months of age at the time of first Nusinersen dose - Must have previously received onasemnogene abeparvovec per the approved label or local/regional regulations ≥2 months prior to first Nusinersen dose - Must have suboptimal clinical status per the Investigator Additional Criteria for Subgroups A and B: - <300 days of age at the time of first Nusinersen dose - SMN2 copy number of 2 Additional Criteria for Subgroup A: - SMA symptom onset ≤4 months (120 days) of age - Must have received intravenous (IV) onasemnogene abeparvovec at >6 weeks to ≤6 months (43 days to 180 days) of age - Must have received IV onasemnogene abeparvovec after SMA symptom onset Additional Criteria for Subgroup B: - Must have received IV onasemnogene abeparvovec at ≤6 weeks (42 days) of age Key
Exclusion Criteria:
  1. For all participants: - Prior exposure to Nusinersen - Ongoing severe or serious AEs related to onasemnogene abeparvovec - Treatment with an investigational drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to study; any prior or current treatment with any survival motor neuron 2 (SMN2)-directed splicing modifier; prior antisense oligonucleotide treatment or cell transplantation; gene therapy for the treatment of SMA other than onasemnogene abeparvovec. Note: treatment with onasemnogene abeparvovec as part of an investigational study is allowed Additional Criteria for Subgroups A and B: - Weight-for-age is below the third percentile, based on WHO Child Growth Standards at the time of receiving onasemnogene abeparvovec. Adjustments for the gestational weight of premature babies enrolled in Subgroups A and B are allowed provided IV onasemnogene abeparvovec was dosed per the approved label or per local/regional regulations. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
View All Criteria
Show Less

Investigator(s)

John W. Day, MD, PhD
John W. Day, MD, PhD
Neuromuscular neurologist, Neurophysiologist
Professor of Neurology (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology

Contact us to find out if this trial is right for you.

Contact


650-725-4341

SEND MESSAGE

View on ClinicalTrials.gov